News for SCYNEXIS, Inc. (SCYX)

California-based Tenon Medical Inc (TNON) is up over 344 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in Q3 of 2025.Four

**media[564897]**

On December 31, 2024, Avidity Partners Management LP (Trades, Portfolio) made a significant move by acquiring an additional 2,763,142 shares of SCYNEXIS Inc. Th

Ironwood Pharmaceuticals (IRWD) experienced a significant stock price decline of 5.30%, trading at $4.20 per share. The trading volume reached 885,652 shares wi

**media[495573]**

SCYX stock touches 52-week low at $1.15 amid market challenges

**media[468722]**

SCYNEXIS announces new $50 million equity sales agreement

**media[433434]**

Overview of Recent Transaction Federated Hermes, Inc., a prominent institutional investor, recently increased its holdings in SCYNEXIS Inc (SCYX) by acquiring a

JERSEY CITY, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome...

Scynexis CEO acquires $27,400 in company stock

Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10...

In this article, we will take a detailed look at the 14 Cheap Penny Stocks to Buy According to Analysts. For a quick overview of such stocks, read our article 5 Cheap Penny Stocks to Buy According...

Shares of Resources Connection, Inc. (NASDAQ: RGP) rose sharply in pre-market trading following better-than-expected results for its second quarter.

In this piece, we will take a look at the 11 cheapest stocks with the biggest upside.

IND enabling development activities for SCY-247, the next generation fungerp from SCYNEXIS’ proprietary antifungal platform, continue to advanceRemediation...

Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138.